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Abstract
Background: Surgeries causing nerve injury can result in chronic neuropathic pain, which is clinically managed by using
antidepressant or anticonvulsant drugs. Currently, there is a growing interest for investigating preemptive treatments that
would prevent this long-term development of neuropathic pain. Our aim was to compare analgesic drugs using two distinct
treatment modalities: either treatment onset at surgery time or following a couple of weeks of neuropathic pain.
Methods: In male C57BL/6J mice, neuropathic pain was induced by cuffing the sciatic nerve, and allodynia was assessed
using von Frey filaments. We tested the effect of anticonvulsants (gabapentin 10mg/kg and carbamazepine 40mg/kg),
antidepressants (desipramine 5mg/kg, duloxetine 10mg/kg, and fluoxetine 10mg/kg), dexamethasone (2mg/kg), and keta-
mine (15mg/kg). Drugs were injected daily or twice a day, starting either at surgery time or on day 25 postsurgery (15 days
of treatment for antidepressants and 10 days for other drugs).
Results: Ketamine was the only effective treatment during the early postsurgical period. Although early anticonvulsant
treatment was not immediately effective, it prevented chronification of allodynia. When treatments started at day 25
postsurgery, desipramine, duloxetine, and anticonvulsants suppressed the mechanical allodynia.
Conclusions: Our data show that allodynia measured in experimental neuropathic pain model likely results from a com-
bination of different processes (early vs. late allodynia) that display different sensitivity to treatments. We also propose that
early anticonvulsant treatment with gabapentin or carbamazepine may have a prophylactic effect on the chronification of
allodynia following nerve injury.
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Introduction
The International Association for the Study of Pain
defines neuropathic pain as a direct consequence of a
lesion or disease affecting the somatosensory system.1
Neuropathic pain is often a chronic and disabling con-
dition that is poorly responsive to usual analgesic drugs.2
The first-line treatments presently recommended against
neuropathic pain are either anticonvulsant drugs, such
as gabapentinoids, or antidepressant drugs, such as tri-
cyclic antidepressants (TCAs) or more selective seroto-
nin and noradrenaline reuptake inhibitors (SSNRIs).3
Surgery is a major cause of chronic neuropathic pain,
with a prevalence estimated between 6% and 68%
depending on the type of surgery.4 The concept of pre-
ventive analgesia aims at decreasing the occurrence of
pain with an early treatment starting in the perisurgical
period. The most frequent targets for preventive analge-
sia are the inflammatory mediators (nonsteroidal
anti-inflammatory drugs), the m-opioid receptors in the
nociceptive pathway (opioid drugs), the N-methyl-D-
aspartate (NMDA) receptor (ketamine), ion channels
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like sodium voltage-gated channels (nerve blocks with
local anesthetics), and the a2-d1 subunit of voltage-
dependent calcium channels (gabapentinoids).5
Although such prevention usually concerns short-term
postsurgical pain, the occurrence of longer term neuro-
pathic pain is less often considered. There is however a
clinical need for preventing such risk of long-term neu-
ropathic pain following surgical procedures. Rodent
models that reproduce peripheral nerve injuries, through
section or compression of the sciatic nerve using a sur-
gical procedure,6 offer the possibility to compare the
long-term impact of perisurgical treatments (“early”
treatment) and of treatments starting a couple of
weeks after neuropathic allodynia appeared (“late”
treatment).
In the present study, we addressed the effect of early
or late treatments on neuropathic allodynia in a model
of sciatic nerve compression. We tested various drugs,
including antidepressants (desipramine, duloxetine, and
fluoxetine), anticonvulsants (gabapentin and carbamaz-
epine), ketamine, and dexamethasone. Treatments were
delivered during 10 to 15 days starting either at surgery
time or after a 25-day delay.
Materials and methods
Animals
Experiments were conducted in the animal facilities
Chronobiotron UMS3415, which are registered for
animal experimentation under the Animal House
Agreement A67-2018-38. All animal protocols were car-
ried out in accordance with European Communities
Council Directive of 22 September 2010 (2010/63/UE),
and approved by the Ethical Committee for Animal
Experimentation of Strasbourg, France (CREMEAS,
CEEA35; authorization no. Al/04/04/01/13).
Experiments were performed using adult male C57BL/
6J mice (n¼ 224 for all the studies, six weeks old upon
arrival; Charles River, L’Arbresle, France). Mice were
group-housed four to five per cage and maintained
under a 12-h light/dark cycle (lights on at 06:00 a.m.),
with food and water available ad libitum. Experiments
started after two weeks of habituation to the animal
facilities. All behavioral assays were performed during
the light period.
Surgery
Neuropathic pain was induced by cuffing the common
branch of the right sciatic nerve.7,8 Surgeries were done
under aseptic conditions and ketamine/xylazine anesthe-
sia (ketamine 68mg/kg i.p., xylazine 10mg/kg i.p.;
Centravet, Taden, France). The common branch of the
right sciatic nerve was exposed, and a 2-mm section of
split PE-20 polyethylene tubing (Harvard Apparatus,
Les Ulis, France) was placed around it (Cuff group).
The shaved skin layer was closed using suture. Sham-
operated mice underwent similar surgical procedure,
without implantation of the cuff (Sham group).
Treatments
Desipramine (5mg/kg i.p.) was used as TCA, duloxetine
(10mg/kg i.p.) as SSNRI, and fluoxetine (10mg/kg i.p.)
as selective serotonin reuptake inhibitor that is clinically
considered as poorly effective against neuropathic pain,
gabapentin (10mg/kg i.p.) or carbamazepine (40mg/kg
s.c.) as anticonvulsants, ketamine (15mg/kg i.p.) as
NMDA receptor antagonist, and dexamethasone
(2mg/kg s.c) as steroidal anti-inflammatory drug.
Preventive treatments began 1 h prior to surgical proce-
dure (cuff implantation or sham operation), while cura-
tive treatments began 25 days after the surgery. Mice
received two injections per day (morning and evening)
of antidepressant drugs, anticonvulsant drugs, or keta-
mine. Dexamethasone was administered once a day.
Antidepressant treatments lasted 15 consecutive days,
based on previously published delayed therapeutic
onset with these drugs in the cuff model of
neuropathic pain.7 The other drugs were administered
for 10 consecutive days. All drugs were purchased
from Sigma-Aldrich (St. Quentin Fallavier, France).
Besides carbamazepine, drugs were dissolved in 0.9%
NaCl solution that was also used for control injections
and were administered in 5 mL/kg volume. The addition
of 1% of Tween 40 was required to prepare a carbamaz-
epine suspension in 0.9% NaCl, which was injected sub-
cutaneously to prevent the risk of peritoneal irritation
with repeated administration.
Nociceptive testing
The mechanical threshold of hindpaw withdrawal was
evaluated using the Semmes-Weinstein von Frey hairs
(Touch test, Stoelting, Ireland), and results were
expressed in grams.8 Mice were placed in clear
Plexiglas boxes (7 9 7 cm) on an elevated mesh
screen. Calibrated monofilaments were applied to the
plantar surface of each hindpaw, in a series of ascending
forces, until they just bend. Brisk withdrawal was con-
sidered as a positive response. In the absence of a
response, a filament of next-greater force was applied.
Each filament was tested five times per paw, and the
threshold was defined as three or more withdrawals
observed out of the five trials.
To study the chronic therapeutic effect, we tested the
animals in the morning, on given days, prior to the injec-
tion of the drug. The tests were initiated prior to the
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surgical procedure (baselines) and pursued until day 50
or 60 postsurgery.
Statistical analysis
Data are expressed as mean SEM. Statistical analyses
were performed with Statistica (Statsoft, Tulsa, OK),
using analysis of variance. Surgical procedure (Sham
vs. Cuff) and treatments (solution of 0.9% NaCl vs.
drugs) were considered as between-group factors and
time points as within-subject factor. When analysis of
variance was significant (P< 0.05), multiple compari-
sons were realized by using the posttest of Duncan.
Results
Treatments with antidepressant drugs
The unilateral insertion of a cuff on the sciatic nerve
induced a long-lasting ipsilateral mechanical allodynia
(F13,156¼ 5.76, P < 0.001; post hoc: cuff baseline> cuff
postsurgery at P< 0.05 on postsurgery days 2–49). In the
Sham group, postsurgical allodynia recovered in a few
days (post hoc: sham baseline> sham postsurgery at
P< 0.05 on postsurgery days 2–6).
We compared the preventive versus curative effects of
three antidepressant drugs: desipramine, duloxetine, and
fluoxetine. Preventive treatments starting 1 h prior to the
surgery and lasting 15 days had no effect on the cuff-
induced allodynia (surgery–treatment time interaction,
desipramine: F13,286¼ 0.93, P¼ 0.52; duloxetine:
F13,273¼ 1.53, P¼ 0.10; fluoxetine: F13,273¼ 0.89,
P¼ 0.55; Figure 1(a), (c), and (e)). However, curative
treatment with desipramine and duloxetine, but not
with fluoxetine, starting 25 days after the surgery fully
suppressed mechanical allodynia (desipramine (Des):
surgery–treatment time interaction, F13,286¼ 2.01, P <
0.005; post hoc: cuffDes> cuffSal at P< 0.05 on post-
surgery days 35–42; Figure 1(b)), (duloxetine (Dulox):
F13,273¼ 2.91, P < 0.001; post hoc: cuffDulox> cuffSal
at P< 0.05 on postsurgery days 35–42; Figure 1(d)), and
(fluoxetine (Fluox): F13,286¼ 0.80, P¼ 0.65; Figure 1(f)).
When desipramine and duloxetine curative treatments
were interrupted, a relapse of mechanical allodynia was
observed (cuffDes< shamDes at P< 0.01 on days 45–49;
cuffDulox< shamDulox at P< 0.001 on days 45–49).
Treatments had no effect either on the paw withdrawal
threshold of Sham mice (Figure 1(b), (d), and (f)) or on
the contralateral paw of Cuff mice (data not shown).
Treatments with anticonvulsant drugs
Early treatments with gabapentin or carbamazepine
began 1 h prior to the surgery and lasted 10 days. At
the end of the 10-day treatment, there was no relief of
allodynia. However, after the end of the treatments, a
gradual improvement in the nociceptive thresholds was
observed in the Cuff mice, leading to full recovery from
allodynia and long-term maintenance of this recovery
(gabapentin (Gaba): surgery–treatment time interaction,
F15,375¼ 2.90, P< 0.001; post hoc: cuffGaba> cuffSal at
P< 0.05 on days 23–59; Figure 2(a); carbamazepine: sur-
gery–treatment time interaction, F15,330¼ 5.37,
P< 0.001; post hoc: cuffCarba> cuffSal at P< 0.05 on
days 23–59; Figure 2(c)). Early treatments thus pre-
vented the allodynia chronification. The same treatments
had no effect either on the paw withdrawal threshold of
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Figure 1. Early and late treatment with the antidepressants
desipramine, duloxetine, and fluoxetine. The mechanical threshold
was evaluated using von Frey hairs, data are represented as mean
 SEM, and n are expressed between brackets. Early 15-day
treatments starting 1 h prior to the surgery with desipramine
(desip 5 mg/kg i.p. twice a day) (a), duloxetine (dulox 10 mg/kg i.p.
twice a day) (c), or fluoxetine (fluox 10 mg/kg i.p. twice a day) (e)
had no effect on allodynia. Later treatments, starting 25 days after
surgery, with desipramine (b) or duloxetine (d) relieved allodynia,
and a relapse was observed after treatment interruption; while the
treatment with fluoxetine (f) had no effect on cuff-induced allo-
dynia. PWT: paw withdrawal threshold.
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Sham mice or on the contralateral paw of Cuff mice
(data not shown).
When treatments started on day 25 postsurgery, i.e., on
animalswith a history of sustained neuropathic pain, gaba-
pentin and carbamazepine alleviated neuropathic allody-
nia after a few days of treatment (gabapentin: surgery–
treatment time interaction, F14,294¼ 6.45, P< 0.001; post
hoc: cuffGaba> cuffSal at P< 0.05 on days 29–44;
Figure 2(b); carbamazepine: F14,294¼ 3.54, P< 0.001;
post hoc: cuffCarba> cuffSal at P< 0.05 on days 31–57;
Figure 2(d)). After 10 days of treatment and total recovery,
the treatments were stopped. A relapse of the neuropathic
allodynia was observed in the two weeks following treat-
ment interruption (gabapentin: cuffGaba< shamSal at
P< 0.05 on days 50–59; Figure 2(b); carbamazepine:
post hoc: cuffCarba> shamSal at P< 0.05 on days
50–59; Figure 2(d)). Treatments had no effect either on
the paw withdrawal threshold of Shammice or on the con-
tralateral paw of Cuff mice (data not shown).
Treatments with ketamine
Early treatment with ketamine led to a progressive
recovery from neuropathic allodynia in Cuff mice.
After 10 days, the treatment with ketamine was inter-
rupted and allodynia slowly reappeared over two
months (surgery–treatment time interaction,
F14,294¼ 2.04, P< 0.01; post hoc: cuffKeta> cuffSal at
P< 0.05 on days 7–44; Figure 3(a)). The late treatment,
starting at day 25 postsurgery, led to a partial recovery
from neuropathic allodynia. After interruption of the
treatment, this partial recovery still remained present
for over 10 days and was followed by a relapse of allo-
dynia (F14,280¼ 2.45, P¼ 0.002; post hoc: cuffKeta>
cuffSal at P< 0.05 on days 31–50; Figure 3(b)).
Treatments with dexamethasone
The early treatment with dexamethasone at high dose did
not significantly modify nociceptive thresholds
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Figure 2. Early and late treatments with the anticonvulsants
gabapentin and carbamazepine. The mechanical threshold was
evaluated using von Frey hairs, data are represented as mean
 SEM, and n are expressed between brackets. Early 10-day
treatments with gabapentin (gaba 10 mg/kg s.c. twice a day) (a) or
carbamazepine (carba 40 mg/kg s.c. twice a day) (c) did not affect
the mechanical thresholds after surgery. After the end of the
treatments, a progressive recovery from allodynia was observed
for both anticonvulsants. Later treatments, starting 25 days after
surgery, with gabapentin (gaba 10 mg/kg s.c. twice a day) (b) or
carbamazepine (carba 40 mg/kg s.c. twice a day) (d) relieved allo-
dynia, and a relapse was observed after treatment interruption.
PWT: paw withdrawal threshold.
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Figure 3. Early and late treatments with ketamine and dexa-
methasone. The mechanical threshold was evaluated using von
Frey hairs, data are represented as mean SEM, and n are
expressed between brackets. Early ketamine treatment (keta 15
mg/kg i.p. twice a day) progressively relieved neuropathic allodynia,
with a relapse of allodynia slowly reappearing over two months (a).
Late ketamine treatment led to a partial recovery, and a relapse
was observed after treatment interruption (b). Early dexametha-
sone treatment (dexa 2 mg/kg s.c. once a day) did not significantly
affect the mechanical thresholds after the surgery (c). Late dexa-
methasone treatment alleviated the allodynia, and a relapse was
observed after treatment interruption (d). PWT: paw withdrawal
threshold.
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(surgery–treatment time interaction, F14,308¼ 1.96,
P¼ 0.02; post hoc: cuffDexa¼ cuffSal at P> 0.05; Figure
3(c)). The late treatment starting 25 days postsurgery
induced a partial recovery of allodynia during the 10 days
of treatment, which further developed into full recovery
during the week following the interruption of the
treatment, and was then followed by a slow relapse of neu-
ropathic allodynia (F14,280¼ 6.57, P< 0.001; post hoc:
cuffDexa> cuffSal atP< 0.05 on days 29–50; Figure 3(d)).
Discussion
Here, we showed that an early and perioperative admin-
istration of anticonvulsant drugs, but not of antidepres-
sant drugs, ketamine, or dexamethasone can prevent the
chronification of neuropathic allodynia in an experimen-
tal model of nerve compression.
Our experiments were not designed to study acute
analgesic action, but rather designed to detect sustained
allodynia relief. This was done by testing the animals in
the morning, before the first drug administration on the
considered day, thus looking at the lasting effect of pre-
vious days of treatment.7 Our results showed that among
all the drugs tested, ketamine was the only one with a
rapid and long-lasting action on the cuff-induced allody-
nia in the early postsurgical period. Approved by the
Food and Drug Administration since 1969 for a clinical
use, ketamine is an analgesic and anesthetic agent, and its
administration during anesthesia decreases postoperative
pain intensity for up to 48 h as well as opioid drugs con-
sumption.9–11 Clinically, perioperative ketamine is also
beneficial on postsurgical inflammatory response.12 This
action of ketamine on pain mechanisms has been mostly
related to its noncompetitive antagonistic action on
NMDA receptors.13
Although ketamine displayed a postsurgical antiallo-
dynic effect that lasted one day to the next, such lasting
action was not observed with a gabapentinoid, a corti-
costeroid or antidepressants when these drugs were given
in the early postsurgical period. However, it should be
noted that it does not preclude the possibility to obtain
short-term transitory pain relief in the postsurgical
period with these other drugs. Indeed, some of them
are routinely used in the clinic. In human, perioperative
gabapentinoids have been clinically well studied14 and
are often used in multimodal analgesia, combining dif-
ferent analgesic drugs. Most studies, but not all of them,
support the benefit of gabapentinoid use on postopera-
tive pain and on the reduction of opioid consumption;
conflicting results being likely associated with treatment
doses and regimens or with the type of surgery.15–23 On
the other hand, animal research is based on single peri-
operative drugs, and only few studies explored the ben-
efit of perioperative gabapentinoids. Recently, Camara
et al.24 reported an analgesic effect of daily oral
gabapentin on mechanical allodynia at days 5 and
15 of sciatic nerve constriction in the rat; but this anti-
allodynic effect was assessed at high doses (30–60–
120mg/kg) and acutely (60 min after the last administration)
(see Table 1). Together with our data, it suggests that
gabapentinoid action on perisurgical pain might be relat-
ed to a short-term transitory analgesia, while another
effect of these drugs would impact pain chronification.
Corticosteroid anti-inflammatory agents have also
shown acute analgesic effects in both human and
animal studies. In experimental models of sciatic nerve
injury, early administration of corticosteroids can in
some cases reduce the inflammatory processes and neu-
ropathic pain behaviors in the days following surgery.25
Clinically, corticosteroids are sometimes used to reduce
inflammatory response after the surgery26; indeed they
can display analgesic and antihyperalgesic effects in
acute experimental27 and postoperative pain.28
However, this action highly depends on the considered
treatment and type of pain,29 and other clinical studies
showed no benefit of perioperative corticosteroids on
acute postoperative pain30 and no delayed benefit at
six weeks or one year after a single perioperative dose
(see Table 1).31 Concerning antidepressants, it has been
shown that duloxetine at high dose can have a transitory
analgesic action when delivered 24 h after paw incision
in the rat,32 and that 10 days of venlafaxine at high dose
can acutely reduce hypersensitivity in a model of sciatic
nerve constriction.33 In both cases, these actions are
however transitory and likely due to the recruitment of
a2-adrenoceptors in descending controls of pain. This
limited action of antidepressants may also be present
clinically. Indeed, in a systematic review evaluating clin-
ical trials of antidepressants for postsurgical pain,34
some beneficial actions of antidepressants on early post-
operative pain were reported in 8 out of 15 trials (see
Table 1). However, adverse effects of these drugs togeth-
er with the high dose that may be required to observe a
perisurgical benefit are limiting the interest in using anti-
depressants in this context. Therefore, they remain more
appropriate against sustained neuropathic pain for
which few therapeutic alternatives are present.
Some antidepressants are among first-line drugs for
neuropathic pain relief.3 TCAs as well as selective
SSNRIs are indeed effective in relieving neuropathic
pain in several animal models and human neuropathic
conditions.35 Accordingly, a 15-day treatment with the
TCA desipramine or the SSNRI duloxetine, starting
three weeks after the surgery, decreased the cuff-
induced mechanical allodynia. In both cases, a relapse
of allodynia was observed after the cessation of the treat-
ments, which is also frequently observed clinically.
Furthermore, in our study, the selective serotonin reup-
take inhibitor fluoxetine was ineffective, which is consis-
tent with several experimental and clinical studies.36
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The most common hypotheses for the analgesic action of
antidepressant drugs35 implicate either the central
recruitment of noradrenergic descending pathways that
inhibit nociceptive responses or the peripheral recruit-
ment of noradrenergic fibers that sprout into the
dorsal root ganglia following peripheral nerve injury.37
Although desipramine and duloxetine displayed antiallo-
dynic action on well-installed neuropathic pain, an early
administration of these drugs in the perioperative period
was ineffective in preventing neuropathic pain chronifi-
cation. Clinically, three trials addressed chronic postsur-
gical pain prevention with antidepressants, using the
SSNRIs duloxetine38 and venlafaxine15 or the selective
serotonin reuptake inhibitor escitalopram.39 Only venla-
faxine, with a 10-day perioperative treatment, was supe-
rior to placebo in reducing burning and stabbing pain six
months after the surgery.15 However, these last results
were obtained in a context of breast surgery, whose
chronification is tightly linked to the emotional profile
of the patients,40 which may be impacted by the antide-
pressant. Results concerning prevention of pain chroni-
fication with antidepressants must be interpreted with
caution and may depend on the considered surgical act.
In the present model of experimental neuropathic
pain, anticonvulsants were the only drugs having a
main impact on allodynia chronification.
Gabapentinoid anticonvulsants, such as gabapentin or
pregabalin, are among first-line treatments for neuro-
pathic pain.3 These drugs bind the a2-d1 subunit of
voltage-dependent calcium channels,41 thus interfering
with channels’ function and trafficking.42 By decreasing
the hyperexcitability of dorsal horn neurons, gabapenti-
noids limit the hyperalgesia and central sensitization
induced by tissue damage and nerve injury.35
Carbamazepine is an older drug43 which remains a
first-line therapy against trigeminal neuralgia3,44 and
also displayed efficacy against painful diabetic neuropa-
thy and postherpetic neuralgia.45 It is a blocker of
voltage-dependent sodium channels,46 but it can also
affect calcium channels.47 In mice, we observed that
both carbamazepine and gabapentin display an antiallo-
dynic effect when administered in a state of chronic neu-
ropathic pain, and that both drugs given for 10 days in
the perioperative period prevented the chronification of
neuropathic allodynia. Some patients do not tolerate
carbamazepine, due to frequent sensations of dizziness,
nausea, and somnolence. It also induces cytochrome iso-
enzymes and can influence the serum levels of other
drugs. Because of this poor tolerability and pharmaco-
kinetic interactions, the use of carbamazepine and its
analog oxcarbamazepine is mostly limited to the treat-
ment of trigeminal neuralgia,48 and no clinical trial has
studied perioperative administrations. However, some
trials addressed the prophylactic action of perioperative
gabapentinoids on chronic postsurgical pain
(see Table 1). A meta-analysis of 11 perioperative gaba-
pentinoids clinical trials was conducted by Clarke et al.14
It suggested that 600mg gabapentin, given once before
surgery, fails to reduce the incidence of chronic pain,17,49
whereas the use of 1200mg may reduce this inci-
dence.16,20,21 Accordingly, our previous clinical work
on thoracotomy-induced chronic pain showed no corre-
lation between a single preoperative dose of 600mg
gabapentin and the incidence of chronic postsurgical
pain.50 When gabapentin administration is prolonged
to the postoperative period, trials’ data on pain reduc-
tion after two months postsurgery are conflicting, but it
has been suggested that the high variability of gabapen-
tin’s bioavailability in patients may interfere and require
controlling for gabapentin plasma level.50 Clinically,
pregabalin has a better absorption profile than gabapen-
tin, and it has been shown in patients that, when given
before surgery and continued for two weeks after the
surgery, pregabalin reduced the incidence of chronic
postsurgical pain following thoracotomy51 or knee
arthroplasty.52 However, these clinical data require con-
firmation through more refined trials, taking also into
account the neuropathic and nociceptive components
of pain. Together with present results in an experimental
model, these findings suggest that the clinical potential
of anticonvulsants in the prevention of long-term neuro-
pathic pain following surgery merits further exploration,
in order to confirm or not the benefit of such treatment,
and to optimize the dose and the most appropriate dura-
tion of treatment in a perioperative context.
As expected, administration of treatments at various
stages of nerve injury has a different impact. Drugs rec-
ommended to treat neuropathic pain (i.e., anticonvul-
sants, TCA, SSNRI), as well as a high dose of
corticosteroid, alleviate chronic neuropathic allodynia.
However, these drugs had no rapid effect on allodynia
when they were administered in the perisurgical period.
Interestingly, the early treatment with gabapentin or car-
bamazepine is prophylactic on the chronification of neu-
ropathic allodynia. Mechanical allodynia is not a unitary
process, but it may combine different mechanisms that
follow different time-courses. In this context, we might
hypothesize that the long lasting decrease in paw with-
drawal thresholds results from at least two distinct
sequences of allodynia (Figure 4(a) and (b)). First, an
early, or postsurgical, allodynia is present, which can be
related to transitory phenomena following the surgical
lesion and acute local nerve inflammation. This allody-
nia may disappear spontaneously in days or weeks after
the surgery and initial nerve compression, and it is sen-
sitive to ketamine. However, at behavioral level, sponta-
neous relief of this early and reversible allodynia is not
detected because of the occurrence of later allodynic
mechanisms. This second type of allodynia results from
sensitization processes and underlies pain chronification,
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with a slow onset during the days following surgery.
Thus, perioperative anticonvulsants may block the
onset of these chronification mechanisms during their
development, while having no impact per se on the
early allodynia (Figure 4(c)). If these mechanisms of
chronification are not blocked at an early stage, gaba-
pentinoids and carbamazepine would then exert a symp-
tomatic and reversible effect (Figure 4(d)), which reflects
their present clinical use.
Here, we used an animal model in which the sustained
neuropathic allodynia is relieved with the same classes of
drugs (gabapentin, antidepressants) as in the clinic, and
with a similar pattern of response (delayed relief, relapse
after the cessation of the treatment). Present results high-
light the importance of a long-term follow up of treat-
ment assessment in experimental models. Indeed,
delayed prophylactic action of drugs on neuropathic
pain may not be detected during the treatment itself.
Surgery is an important cause of lasting neuropathic
pain, and while preventive analgesia often addresses
short-term postsurgical pain, the risk of neuropathic
pain chronification is less often studied, despite the clin-
ical need for preventing such long-term risks.
Our main finding is the presence of a delayed preemp-
tive and long-lasting antiallodynic action with a 10-day
early anticonvulsant drug treatment, leading to a persist-
ing absence of allodynia two months after the surgery.
These results support the interest for further clinical
assessment of preventive prolonged anticonvulsant treat-
ment with gabapentinoids for reducing the long-term
risk of postsurgical neuropathic pain.
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